
Claims

1. A compound of formula III:



or a pharmaceutically acceptable salt thereof,

wherein:

R^1 is: C_{1-6}alkyl; or halo;

R^2 is: C_{3-6}cycloalkyl; C_{1-6}alkoxy-C_{1-6}alkyl; hydroxy-C_{1-6}alkyl; or heteroaryl-C_{1-6}alkyl selected from the group consisting of pyrazinyl-methyl and pyridazinyl-methyl; wherein the pyrazinyl and pyridazinyl portions thereof may be optionally substituted once with methyl;

R^3 is: C_{1-6}alkyl; ~~hydroxy-C_{1-6}alkyl;~~ C_{1-6}alkoxy-C_{1-6}alkyl; halo-C_{1-6}alkyl; ~~C_{3-6}cycloalkyl; C_{3-6}cycloalkyl-C_{1-6}alkyl;~~ phenyl optionally substituted with halo, C_{1-6}alkyl, C_{1-6}alkoxy or halo-C_{1-6}alkyl; or phenyl-C_{1-6}alkyl wherein the phenyl portion thereof is optionally substituted with halo, C_{1-6}alkyl, C_{1-6}alkoxy or halo- C_{1-6}alkyl;

~~R^4 and R^5 each independently is: hydrogen; or fluoro;~~

X is: N; ~~or CR^a wherein R^a is C_{1-6}alkyl or halo;~~.

~~Y is: N; or CR^b wherein R^b is hydrogen or C_{1-6}alkyl; and~~

~~Z is: N; or CR^c; wherein R^c is hydrogen or C_{1-6}alkyl.~~

~~2. The compound of claim 1, wherein R^4 and R^5 are hydrogen.~~

~~3~~2. The compound of claim ~~2~~1, wherein R^1 is methyl.

~~4~~3. The compound of claim ~~2~~1, wherein R^2 is: cyclopropyl; 2-methoxy-1-methyl-ethyl; 2-hydroxy-1-methyl-ethyl; 5-methylpyrazin-2-yl-methyl; 1-pyrazin-2-yl-ethyl; ~~pyrimidin-5-yl-methyl;~~ 6-methyl-pyridazin-3-yl-methyl~~;~~ or pyridazin-3-yl-methyl; ~~5-methyl-pyrimidin-yl-methyl; or 2-methyl-pyrimidin-5-yl-methyl~~.

~~5~~4. The compound of claim ~~2~~1, wherein R^3 is C_{1-6}alkyl; halo-C_{1-6}alkyl; phenyl optionally substituted with C_{1-6}alkyl; or phenyl-C_{1-6}alkyl wherein the phenyl portion thereof is optionally substituted with C_{1-6}alkyl.

~~6~~5. The compound of claim ~~2~~1, wherein R^3 ~~is~~ is isopropyl, isobutyl, n-propyl, 3-methyl-butyl, 2,2,2-trifluoroethyl, 2-methoxyethyl, phenyl, benzyl, 2-methyl-phenyl; 4-methyl-phenyl; or 2-isopropyl-phenyl.

~~7~~6. The compound of claim ~~2~~1, wherein R^3 ~~is~~ is isopropyl, isobutyl, n-propyl, or 3-methyl-butyl.

~~8~~7. The compound of claim ~~2~~1, wherein R^3 is phenyl, 2-methyl-phenyl; 4-methyl-phenyl; or 2-isopropyl-phenyl.

~~9~~8. The compound of claim ~~2~~1, wherein X is -N-.

~~10. The compound of claim 2, wherein X is $-CR^a-$.~~

~~11. The compound of claim 10, wherein R^a is hydrogen or halo.~~

~~12. The compound of claim 2, wherein Y is N or wherein Y is CR^b.~~

~~13. The compound of claim 2, wherein Z is N or wherein Z is CR^e.~~

~~14. The compound of claim 2, wherein Y is CR^b and Z is CR^e.~~

~~15~~9. A compound according to any one of claims 1 to ~~14~~ 8 selected from the group consisting of:

1-Isobutyl-4-(5-methyl-pyridin-2-yl)-1H-indazole-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide;

1-Butyl-4-(5-methyl-pyridin-2-yl)-1H-indazole-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide;

1-Butyl-4-(5-methyl-pyridin-2-yl)-1H-indazole-6-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide;

1-Isopropyl-4-(5-methyl-pyridin-2-yl)-1H-indazole-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide;

1-Isopropyl-4-(5-methyl-pyridin-2-yl)-1H-indazole-6-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide;

1-(2-Methoxy-ethyl)-4-(5-methyl-pyridin-2-yl)-1H-indazole-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide;

1-(3-Methyl-butyl)-4-(5-methyl-pyridin-2-yl)-1H-indazole-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide;

1-(3-Methyl-butyl)-4-(5-methyl-pyridin-2-yl)-1H-indazole-6-carboxylic acid (6-methyl-pyridazin-3-ylmethyl)-amide;

1-Benzyl-4-(5-methyl-pyridin-2-yl)-1H-indazole-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide;

1-Benzyl-4-(5-methyl-pyridin-2-yl)-1H-indazole-6-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide;

1-Benzyl-4-(5-methyl-pyridin-2-yl)-1H-indazole-6-carboxylic acid (6-methyl-pyridazin-3-ylmethyl)-amide;

4-(5-Methyl-pyridin-2-yl)-1-(2,2,2-trifluoro-ethyl)-1H-indazole-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide;

4-(5-Methyl-pyridin-2-yl)-1-(2,2,2-trifluoro-ethyl)-1H-indazole-6-carboxylic acid (6-methyl-pyridazin-3-ylmethyl)-amide;

4-(5-Methyl-pyridin-2-yl)-1-phenyl-1H-indazole-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide;

4-(5-Methyl-pyridin-2-yl)-1-phenyl-1H-indazole-6-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide;

4-(5-Methyl-pyridin-2-yl)-1-p-tolyl-1H-indazole-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide;

4-(5-Methyl-pyridin-2-yl)-1-p-tolyl-1H-indazole-6-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide;

4-(5-Methyl-pyridin-2-yl)-1-o-tolyl-1H-indazole-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide;

4-(5-Methyl-pyridin-2-yl)-1-o-tolyl-1H-indazole-6-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide; and

1-(2-Isopropyl-phenyl)-4-(5-methyl-pyridin-2-yl)-1H-indazole-6-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide; and

~~1-Isobutyl-4-(5-methyl-pyridin-2-yl)-1H-indole-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide;~~

~~1-Isobutyl-4-(5-methyl-pyridin-2-yl)-1H-indole-6-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide;~~

~~4-(5-Methyl-pyridin-2-yl)-1-phenyl-1H-indole-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide;~~

~~4-(5-Methyl-pyridin-2-yl)-1-phenyl-1H-indole-6-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide;~~

~~1-Isopropyl-4-(5-methyl-pyridin-2-yl)-1H-indole-6-carboxylic acid (6-methyl-pyridazin-3-ylmethyl)-amide;~~

~~1-Isopropyl-4-(5-methyl-pyridin-2-yl)-1H-indole-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide;~~

~~1-Isopropyl-4-(5-methyl-pyridin-2-yl)-1H-indole-6-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide;~~

~~3-Isobutyl-7-(5-methyl-pyridin-2-yl)-3H-benzoimidazole-5-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide; and~~

~~3-Isobutyl-7-(5-methyl-pyridin-2-yl)-3H-benzoimidazole-5-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide; and~~

pharmaceutically acceptable salts therof.

~~16~~10. A compound according to any one of claims 1 to ~~15~~ 9 for use as therapeutically active substance.

~~17~~11. A compound according to any of claims 1 to ~~15~~ 9 for use in the treatment of a urinary tract disease selected from reduced bladder capacity, frequenct micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benign prostatic hypertrophy, prostatitis, detrusor hyperreflexia, urinary frequency, nocturia, urinary urgency, overactive bladder, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity; or for use in the treatment of a pain condition selected from inflammatory pain, surgical pain, visceral pain, dental pain, premenstrual pain, central pain, pain due to burns, migraine or cluster headaches, nerve injury, neuritis, neuralgias, poisoning, ischemic injury, interstitial cystitis, cancer pain, viral, parasitic or bacterial infection, post-traumatic injury, or pain associated with irritable bowel syndrome.

~~18~~12. A pharmaceutical composition comprising: (a) a pharmaceutically acceptable carrier; and (b) a compound of any one of claims 1 to ~~15~~9.

~~19~~13. The use of a compound according to any one of claims 1 to ~~15~~9, for the preparation of a medicament for the treatment of a urinary tract disease selected from reduced bladder capacity, frequenct micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benign prostatic hypertrophy, prostatitis, detrusor hyperreflexia, urinary frequency, nocturia, urinary urgency, overactive bladder, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity; or for the treatment of a pain condition selected from inflammatory pain, surgical pain, visceral pain, dental pain, premenstrual pain, central pain, pain due to burns, migraine or cluster headaches, nerve injury, neuritis, neuralgias, poisoning, ischemic injury, interstitial cystitis, cancer pain, viral, parasitic or bacterial infection, post-traumatic injury, or pain associated with irritable bowel syndrome.